SARS-CoV-2 Membrane-, Envelope-, Nucleoprotein protein-VLP

Catalog No. ABIN7538787

This VLP protein is expressed in HEK-293 Cells.

Quick Overview for SARS-CoV-2 Membrane-, Envelope-, Nucleoprotein protein-VLP (ABIN7538787)

Target: SARS-CoV-2 Membrane-, Envelope-, Nucleoprotein

Protein Type: VLP

Origin: SARS Coronavirus-2 (SARS-CoV-2)

Source: HEK-293 Cells

Application: ELISA, Nanoparticle Tracking Analysis (NTA), Western Blotting (WB), Lateral Flow (LF)

Product Details

Purpose: VLP of SARS-CoV-2 (M+E+N)

Characteristics: SARS-CoV-2 virus-like particles (VLP) were produced in HEK cells by co-expression of the membrane-, envelope- and nucleoprotein. The VLPs do not contain the viral genome, cannot replicate and are not infectious.

Purification: Tangential flow filtration and polyethylene glycol precipitation

Biological Activity Comment: active

Application Details

Application Notes: Applications: Immunogenic antigen, antigen for ELISA and Western blot, reference for rapid antigen tests.
Western blot: 1-10 μg, ELISA: 1-5 μg/mL

Comment:

Virus-like Particles are multiprotein complexes that resemble a native virus, but lack the genetic information. Therefore, VLPs are safe to handle in numerous fields of applications. For example, VLPs can be applied as antigen in serological assays (e.g. ELISA), or serve as reference material to standardize the performance of different diagnostic tests (e.g. rapid antigen tests or ELISA). Due to the self-adjuvanting properties of VLPs is the most common application of VLPs the use as antigen for immunizations for vaccine development or antibody discovery campaigns.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: Lot specific

Buffer: PBS

Storage: -80 °C

Storage Comment: - 80°C

Target Details

Target: SARS-CoV-2 Membrane-, Envelope-, Nucleoprotein

Background: SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) is a coronavirus (genus: Betacoronavirus, subgenus: Sarbecovirus) that was identified as the cause of COVID-19 disease in early 2020.